151 material Form 8-K filings that 136 companies we cover made with the SEC in February 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Pure Storage reported fiscal fourth-quarter 2024 revenue of $789.8 million, down 3% from a year earlier, while full-year revenue rose 3% to $2.8 billion. Fourth-quarter GAAP operating income fell to $57.4 million from $64.6 million, and diluted EPS was $0.20 versus $0.22. The company guided fiscal 2025 revenue to $3.1 billion and authorized up to an additional $250 million in share repurchases.
Q4 revenue $789.8 million, down 3% year-over-year; subscription services revenue $328.9 million, up 24%
Full-year fiscal 2024 GAAP net income $61.3 million, versus $73.1 million in fiscal 2023
EMCOR reported record fourth-quarter and full-year 2023 revenue and diluted earnings per share, and its board approved a quarterly dividend increase to $0.25 per share from $0.18. The company also guided 2024 revenue to $13.5 billion-$14.0 billion and diluted EPS to $14.00-$15.00, above 2023 levels.
Q4 2023 revenue $3.44 billion, up 16.6%; Q4 diluted EPS $4.47 versus $2.63 a year earlier
Full-year 2023 revenue $12.58 billion, up 13.6%; diluted EPS $13.31 versus $8.10 in 2022
TG Therapeutics reported fourth quarter and full year 2023 results, furnished as Exhibit 99.1 to a Form 8-K. Full-year total revenue was $233.7 million, including a $140.0 million one-time payment from Neuraxpharm, and the company swung to net income of $12.7 million from a $198.3 million net loss in 2022. The company also set a 2024 BRIUMVI U.S. net product revenue target of $220 million to $260 million, giving shareholders a benchmark for future results.
Q4 2023 total revenue was $44.0 million versus $80 thousand in Q4 2022; Q4 net loss narrowed to $14.4 million from $53.0 million.
Full-year 2023 BRIUMVI U.S. net product revenue was $88.8 million; license, milestone and other revenue was $141.7 million, mainly from the $140.0 million Neuraxpharm payment received in July 2023.
2024 targets: BRIUMVI U.S. net product revenue of approximately $220 million to $260 million and total operating expense of approximately $250 million.
Year-end 2023 cash, cash equivalents and investment securities were $217.5 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.